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ABSTRACT
Tumor cells can interact with neighboring adipose tissue. We evaluated 
components present in human adipose explants from normal (hRAN) and kidney 
cancer (hRAT) tissue, and we evaluated the effects of conditioned media (CMs) 
from hRAN and hRAT on proliferation, adhesion and migration of tumor and non-
tumor human renal epithelial cell lines. In addition, we evaluated the expression of 
AdipoR1, ObR, CD44, vimentin, pERK and pPI3K on cell lines incubated with CMs. 
hRAN were obtained from healthy operated donors, and hRAT from patients who 
underwent a nephrectomy. hRAT showed increased levels of versican, leptin and ObR; 
and decreased levels of perilipin, adiponectin and AdipoR1, compared to hRAN. Cell 
lines showed a significant decrease in cell adhesion and increase in cell migration 
after incubation with hRAT-CMs vs. hRAN- or control-CMs. Surprisingly, HK-2, 786-
O and ACHN cells showed a significant decrease in cell migration after incubation 
with hRAN-CMs vs. control-CMs. No difference in proliferation of cell lines was found 
after 24 or 48 h of treatment with CMs. AdipoR1 in ACHN and Caki-1 cells decreased 
significantly after incubation with hRAT-CMs vs. hRAN-CMs and control-CMs. ObR and 
CD44 increased in tumor line cells, and vimentin increased in non-tumor cells, after 
incubation with hRAT-CMs vs. hRAN-CMs and control-CMs. We observed an increase 
in the expression of pERK and pPI3K in HK-2, 786-O and ACHN, incubated with hRAT-
CMs. In conclusion, results showed that adipose microenvironment can regulate the 
behavior of tumor and non tumor human renal epithelial cells.
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INTRODUCTION
In addition to the epigenetic and genetic changes 
that occur in epithelial cells, in recent years it has been 
shown that tumor progression also depends on the 
bidirectional dialogue between tumor epithelial cells and 
surrounding stromal cells. Among the different types of 
cells that share microenvironment with renal epithelial 
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cells, renal adipose tissue is one of the most abundant. 
Adipose tissue is a bioactive endocrine organ [1, 2], 
highly metabolic [3], that not only secretes soluble factors 
but also contributes significantly to the composition of the 
extracellular matrix (ECM). Adipose tissue has distinctive 
characteristics depending on its location [4]. For example, 
visceral adipose tissue presents anatomical, cellular and 
expression profiles different from subcutaneous adipose 
tissue [5]. Recent studies have shown that growth factors 
and cytokines secreted by adipose tissue have a significant 
impact on the progression of different diseases, including 
cancer [2, 6–12]. Renal cancer or renal cell carcinoma 
(RCC), is considered the fifth most frequent cancer 
type worldwide, and is related to a high mortality rate 
in both men and women [13]. RCC currently accounts 
for 90% of all new renal malignancies [14]. Established 
risk factors include tobacco smoking, body size, and 
history of hypertension and chronic kidney disease. 
Additionally, it has been suggested that additional 
underlying biological mechanisms might be responsible 
for disease occurrence. However, this hypothesis requires 
additional investigations [15]. It is known that the large 
amount of adipokines secreted by adipose tissue can act 
in an autocrine, paracrine and / or endocrine form and 
in this way control various cellular processes. Leptin and 
adiponectin are the most studied adipokines, since they are 
the most highly expressed by adipose tissue [16]. It has 
been postulated that leptin would have a pro-tumorigenic 
while adiponectin, an anti-tumorigenic function 
[17, 18]. Furthermore, it has been shown that leptin has 
pro-angiogenic effects while adiponectin can induce 
apoptosis of tumor cells [19–22]. An over-expression of 
leptin receptors (ObR) has been recently found in some 
cancer types [23]. In RCC patients, adiponectin levels 
are reduced and correlate inversely with the size of 
the tumor [24]. Versican may also interfere with tumor 
progression [25, 26]. Different studies have described that 
versican stimulates cell growth and inhibits cell adhesion 
[27], both processes related to tumor progression [28, 
29]. The functional diversity of versican is dependent 
upon its concentration [30, 31]. In fact, it has been seen 
that the interaction between versican and CD44 affects 
the proliferation and motility of tumor cells [30, 32]. 
Versican is also cleaved by ADAMTS1 protease and 
its product of proteolysis is involved in migratory and 
vascularization processes [33]. Zi et al. [34] demonstrated 
that secreted factors from perineoplasm perinephric 
adipose tissue (PAT) might play a role in facilitating 
metastasis or perirenal fat invasion of clear-cell renal 
carcinoma (ccRCC), by mobilizing ccRCC cells away 
from primary tumor sites. We recently demonstrated that 
human adipose tissue from renal cell carcinoma near the 
tumor (hRATnT), regulates the behavior of tumor and 
non-tumor human renal epithelial cells differently than 
adipose tissue farther away from the tumor (hRATfT) 
[11]. Specifically, we observed that hRATnT-CMs 
differentially regulate the adhesion and migration of renal 
tumor and non-tumor epithelial cell lines, compared to 
hRATfT-CMs, without modifying their proliferation. In 
addition, we found that hRATnT secretes greater amounts 
of leptin and versican than hRATfT. Finally, we observed 
that human tumor and non-tumor renal epithelial cells 
incubated with hRATnT-CMs, decreased the expression of 
adiponectin type 2 receptor and modified the activation of 
PI3K and Akt, compared to the same cells incubated with 
hRATfT- or control-CMs [11]. In the present work, the 
microenvironment studied was human renal adipose tissue 
from: 1) patients with renal tumors (hRAT), and 2) healthy 
living kidney donors (hRAN). We identified soluble and 
non-soluble components present in the different fragments 
of adipose tissue (hRAN or hRAT), and their respective 
conditioned media (CMs), by qRT-PCR, Western blot 
and immunohistochemistry. In addition, we determined 
the effect of soluble factors released by these different 
adipose tissues on proliferation, adhesion and migration 
in different human renal cell lines (tumor and non-
tumor); treated with the hRAN- or hRAT-CMs. Finally, 
we characterized factors that are modified in human renal 
cell lines, when incubated with hRAN- or hRAT-CMs. 
In particular, we evaluated: 1) changes in the expression 
of adiponectin, leptin receptors, CD44 as well as pERK 
and pPI3K as possible intracellular molecules that might 
be responsible for the different biological responses we 
studied; and 2) changes in the expression of vimentin, 
as a marker of the epithelial-mesenchymal transition, a 
characteristic process of epithelial cells when they acquire 
migratory capacity.
RESULTS
Versican and leptin gene expression was 
increased in hRAT compared to hRAN, while 
adiponectin gene expression was not modified
We measured gene expression (mRNA levels) of 
adiponectin, leptin and versican, in adipose tissue explants 
from normal (hRAN) and tumor (hRAT) kidney. Results 
showed an increase of versican and leptin mRNA level 
in hRAT compared to hRAN (Figure 1, p < 0.05). No 
significant differences were found in adiponectin mRNA 
expression (Figure 1).
Perilipin 1 protein expression in hRAT-CMs 
showed decreased levels compared to hRAN-
CMs, while adiponectin and ADAMTS 1 protein 
expression was not modified
Protein quantification (total amount) was performed 
in the conditioned media: hRAN-CMs: 2.12 ± 0.25 µg/
µl (n = 12), and hRAT-CMs: 1.71 ± 0.29 µg/µl (n = 12) 
(p < 0.05).
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We evaluated the expression of perilipin1, 
adiponectin and ADAMTS1 1 in hRAT- and hRAN-CMs. 
Our results indicated a decreased expression of perilipin 
1 in hRAT-CMs compared to hRAN-CMs (Figure 2, 
p < 0.01). This result could indicate that adipocytes from 
a tumor’s microenvironment have a less differentiated 
state than adipocytes from a normal microenvironment. 
No significant differences were found in adiponectin and 
ADAMTS1 (Figure 2).
ObR expression was increased while AdipoR1, 
adiponectin and perilipin 1 protein expression 
was decreased in hRAT adipocytes compared to 
hRAN
In order to measure ObR, AdipoR1, adiponectin 
and perilipin 1 levels and localization in both tissue 
samples, we performed immunohistochemistry assays 
on adipose tissue explants from normal (hRAN) and 
tumor (hRAT) kidney. We found increased levels of ObR 
expression (Figure 3, p < 0.01) and a decrease in AdipoR1, 
adiponectin and perilipin 1 expression (Figure 3, p < 0.01), 
in hRAT adipocytes compared to hRAN adipocytes.
Proliferation of 786-O, ACHN, Caki-1 (tumor) 
and HK-2 (non-tumor) cells was not modified by 
hRAN- or hRAT-CMs
In order to identify proliferation and cellular viability, 
an MTT assay and cell counting with Tripan blue were 
performed, finding in both cases consistent results. After 
incubating for 24 h or 48 h, proliferation was not modified in 
any of the cell lines studied, independently of the treatment 
performed (hRAN-, hRAT- or control-CMs) (Figure 4).
Cellular adhesion of 786-O, ACHN, Caki-1 and 
HK-2 cells lines treated with hRAT-CMs was 
decreased. Adhesion of HK-2 (non-tumor) cells 
was increased after incubation with hRAN-CMs
786-O, ACHN, Caki-1 and HK-2 cells were seeded 
in plates previously exposed to different CMs. hRAT-
Figure 1: Relative fold expression of versican, adiponectin and leptin gene expression from hRAN and hRAT. The 
mRNA profiles of versican, adiponectin and leptin from different adipose tissue were analyzed by qRT-PCR and normalized by their 
relative ratio to GAPDH. Data are mean ± SEM. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *p < 0.05.
Figure 2: Adiponectin, ADAMTS1 and perilipin 1 in hRAN- and hRAT-CMs. Adiponectin, ADAMTS1 and perilipin 1 
expression was evaluated by Western blot. Images were analyzed by densitometry. Horizontal bars represent the geometric mean of each 
data set. Vertical bars indicate SEM. *p < 0.05 hRAN-CMs vs. hRAT-CMs.
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CMs significantly reduced the adhesion of all cell lines 
compared to hRAN-CMs and control-CMs (Figure 5, 
p < 0.05). Surprisingly, HK-2 cells showed a significant 
increase in cell adhesion (p < 0.05) after incubation with 
hRAN-CMs vs. control-CMs.
Migration of 786-O, ACHN, Caki-1 (tumor), 
and HK-2 (non-tumor) cells increased after 
incubation with hRAT-CMs, while the migration 
of 786-O, ACHN and HK-2 cells was decreased 
post incubation with hRAN-CMs
After incubating for 6 h, hRAT-CMs significantly 
increased migration of 786-O, ACHN and Caki-1 (p 
< 0.001). Similarly, after incubating for 12 h, hRAT-
CMs significantly increased (p < 0.001) migration of 
HK-2, vs. the effect of hRAN-CMs and control-CMs 
(Figure 6A). Transwell migration assays showed a 
similar pattern: transmigration of all cell lines increased 
significantly when they were incubated with hRAT-CMs 
vs. hRAN-CMs and control-CMs (p < 0.001) (Figure 
6B). Interestingly, HK-2, 786-O and ACHN cells 
showed a significant decrease in cell migration (p < 
0.05) after incubation with hRAN-CMs vs. control-CMs 
(Figure 6).
In tumor renal cancer cells incubated with 
hRAT-CMs, AdipoR1 expression was diminished, 
while ObR and CD44 expression was increased. 
In addition, hRAT-CMs increased the expression 
of vimentin in HK-2 cells
We evaluated possible changes in the expression 
of AdipoR1, ObR, CD44 receptors and vimentin, in 
the different cell lines incubated with the CMs (hRAT-, 
hRAN- or control-CMs).
Figure 3: ObR, AdipoR1, adiponectin and perilipin 1 expression in the different adipose tissues. ObR, AdipoR1, adiponectin 
and perilipin 1 expression was evaluated by immunohistochemistry in serial cuts of hRAN and hRAT. DAB staining quantification in the 
three tissue types was performed with Image J software (NIH). Histograms show mean ± SEM of six independent experiments. (a. u.: 
arbitrary units). *p < 0.01 hRAN vs. hRAT. Representative photographs of hRAN- and hRAT-staining. Magnification: ×100.
Figure 4: Effect of CMs from hRAN and hRAT on proliferation of HK-2, 786-O, ACHN and Caki-1 cell lines. HK-
2, 786-O, ACHN and Caki-1 cell lines were incubated with hRAN- (n = 13), hRAT- (n = 14) or control-CMs for 24 (A) or 48 h (B). 
Proliferation was measured by MTT assays. Data are shown as the mean ± SEM (n = 4–5 experiments by triplicate). 
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Figure 5: Effect of CMs from hRAN and hRAT on HK-2, 786-O, ACHN and Caki-1 cell lines attachment. HK-2, 786-O, 
ACHN and Caki-1 cell lines were plated at a density of 5 × 104 cells/well in wells preincubated ON with hRAN- (n = 10–13), hRAT- (n = 
10–13) or control-CMs and adherent cells were quantified by MTT. Data are shown as the mean ± SEM (n = 3 experiments by triplicate). 
*p < 0.05 hRAT-CMs vs. hRAN-CMs and control-CMs; **p < 0.05 hRAN-CMs vs. control-CMs.
Figure 6: Effect of CMs from hRAN and hRAT on migration of HK-2, 786-O, ACHN and Caki-1 cell lines. Wound 
healing assay (A) HK-2, 786-O, ACHN and Caki-1 cell lines were grown with hRAN- (n = 10–13), hRAT- (n = 10–14) or control-CMs by 
additional 24 hs. After that, cells were wounded, washed twice with PBS and hRAN- (n = 13), hRAT- (n = 14) or control-CMs were added. 
Images were captured at the wound instant (0 h), after 6 and 12 hs. Representative light microscopic images (4×) are shown. HK-2, 786-O, 
ACHN and Caki-1 cell lines were incubated with hRAN-, hRAT- or control-CMs. The histogram shows the ratio of 12 hs/0 hs (HK-2) or 
6 hs/0 hs (786-O, ACHN and Caki-1) cutting area and is plotted as mean ± SEM (n = 4 experiments by duplicate). *p < 0.001 hRAT-CMs 
vs. hRAN-CMs and control-CMs; **p < 0.05 hRAN-CMs vs. control-CMs. Transmigration assay (B): HK-2, 786-O, ACHN and Caki-1 
cells were incubated with hRAN- (n = 10), hRAT- (n = 10) or control-CMs allowed to migrate across the porous membrane for 24 hs. The 
membranes were viewed under 20× magnification and migrated cells were counted in 5 randomly chosen fields per membrane. Data are 
shown as the mean ± SEM (n = 3 experiments by duplicate). *p < 0.001 hRAT-CMs vs. hRAN-CMs and control-CMs; **p < 0.05 hRAN-
CMs vs. control-CMs.
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We observed a decrease in AdipoR1 expression in 
ACHN and Caki-1 (tumor cells) incubated with hRAT-
CMs compared to hRAN- and control-CMs (p < 0.001) 
(Figure 7A). In addition, ObR expression in 786-O, ACHN 
and Caki-1 (tumor cells) was significantly higher when 
these cells were incubated with hRAT-CMs compared 
to hRAN- and control-CMs (p < 0.001) (Figure 7B). 
Additionally, CD44 expression in ACHN and Caki-1 cells 
was significantly higher when these cells were incubated 
with hRAT-CMs compared to hRAN- and control-CMs 
(p < 0.001) (Figure 7C). Finally, we observed an increase 
in vimentin expression in HK-2 (non-tumor cell) incubated 
with hRAT-CMs compared to hRAN- and control-CMs 
(p < 0.001) (Figure 7D).
hRAT-CMs increased pERK expression in HK-2 
and 786-O cells after 2 h of incubation, and 
increased pPI3K expression in HK-2, 786-O and 
ACHN cells after 24 h of incubation
In order to elucidate possible intracellular 
mechanisms involved in the observed biological effects 
(e. g. changes in cell adhesion and migration), we studied 
the expression of some intracellular proteins involved 
in different signaling pathways that activate gene 
transcription (for instance pERK and pPI3K). We found 
an increase in pERK expression in HK-2 and 786-O cells 
incubated for 2 h with hRAT-CMs compared to hRAN- 
and control-CMs (p < 0.001) (Figure 8A). Furthermore, 
pPI3K expression in HK-2, 786-O and ACHN cells 
increased significantly when these cells were incubated 
with hRAT-CMs compared to the value observed with 
hRAN- and control-CMs (Figure 8B, p < 0.001).
DISCUSSION
In tumor development and maintenance of a 
cancerous phenotype (whether invasive or not), 
bidirectional communication between epithelial cells and 
the stromal environment is necessary. This communication 
can trigger a cancerous behavior as well as act in its 
maintenance or eventual involution to a non-tumor form. 
Our group has shown that periprostatic adipose tissue from 
prostate cancer patients could influence tumor behavior 
even at early stages [35]. Furthermore, we have worked 
with adipose tissue fragments from human breast tumors 
(hATT) and normal breast glands (hATN), from which we 
obtained the corresponding conditioned media (hATT-
CMs and hATN-CMs, respectively) [9, 10, 12]. Based on 
these results, we could demonstrate the importance of 
epithelial cell microenvironment, in particular of human 
adipose tissue, in the regulation of growth and metastasic 
capacity of human breast epithelial cells. Thus, in the 
present study we aimed to evaluate the effect of human 
renal adipose tissue from normal and cancerous kidney on 
renal epithelial cells. Adipose tissue is the most prevalent 
tissue in the human body. It is commonly found in 
subcutaneous connective tissue and also surrounding 
various organs including the kidneys [24]. This tissue can 
produce and secrete a variety of cytokines [36, 37]. 
Among them is adiponectin, which has been linked to 
different diseases. Low serum levels of adiponectin have 
been related to obesity, insulin resistance, metabolic 
syndrome, atherosclerosis, and cancer [38, 39]. AdipoR1 
(one of the adiponectin receptors), has been of interest in 
cancer research because of its anti-tumorigenic role 
described when interacting with its ligand [38, 40]. In 
agreement with the possibility that adipose tissue from a 
normal microenvironment has a protective role on the 
surrounding tissue, we found that hRAT have decreased 
levels of adiponectin and AdipoR1 compared to hRAN 
(Figure 3). On the other hand, leptin has an opposite 
function in comparison with adiponectin. In obese people, 
serum leptin levels are usually increased [3, 41]. Obesity 
is a risk factor for various diseases, including cancer [42]. 
Leptin is a hormone that regulates adipocyte size, as well 
as the development of certain tumor types. Its involvement 
in tumor development would seem to be related to its 
antiapoptotic, mitogenic and proangiogenic effects. In 
addition, leptin promotes murine renal cancer cell 
invasiveness through extracellular signal-regulated kinase 
signaling pathway, and guanosine-Rho triphosphate 
dependent pathways [43]. Therefore, leptin signaling 
could have a key role in renal cancer cell invasion. We 
found a significant increase in leptin and its ObR receptor 
in hRAT adipocytes with respect to hRAN adipocytes 
(Figures 1 and 3). In addition, in the present work, we 
found that adipocytes from tumor microenvironment 
express diminished levels of perilipin-1 (Figures 2 and 3). 
Perilipin-1 is found in the membrane surrounding lipid 
droplets and in the plasma membrane, and its expression 
is associated with mature adipocytes [44]. Some authors 
have observed that adipocytes exposed to factors secreted 
by tumor cells revert to a more undifferentiated state, and 
that the conditioned medium of these adipocytes promotes 
the migration of tumor epithelial cells [45]. Therefore, our 
results suggest that adipocytes from tumor 
microenvironment revert to a less differentiated state and 
that this probably implies a change in their functions. 
Likewise, we observed that versican is increased in hRAT 
compared to hRAN samples (Figure 1). Therefore, 
versican could be playing a role in fat cells. Several studies 
have shown that versican seems to be involved in diverse 
cell functions such as adhesion, migration and proliferation 
[32]. Interestingly, it has been described that during 
adipose differentiation processes, adipokines increase the 
production of proteoglycans (among them versican) in a 
3T3-L1 fibroblastic murine cell line [46]. However, once 
cells reach a differentiated mature state, this production 
falls below the parental cell line level [47]. Thus, the 
increase of versican would appear to be related to the first 
stages of the differentiation process to adipocytes, and 
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Figure 7: Effect of CMs from hRAN and hRAT on: AdipoR1 (A); ObR (B), CD44 (C) and vimentin (D) expression was evaluated in 
HK-2, 786-O, ACHN and Caki-1 cell lines. HK-2, 786-O, ACHN and Caki-1 cells were grown on 6 well plates, incubated for 24 hs with 
the different CMs and then lysed. Expression of the different proteins was measured by Western blot. β-actin was used as internal control. 
Images were analyzed by densitometry Horizontal bars represent the geometric mean of each data set. Vertical bars indicate SEM. *p < 
0.001 cells incubated with hRAT-CMs vs. hRAN-CMs and control-CMs.
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would be expressed by cells in intermediate stages of 
differentiation. Therefore, versican increase in hRAT 
adipocytes could be associated to the reversal of mature 
state adipocytes to a less differentiated state, in agreement 
with the observed decrease of perilipin-1 expression. The 
lower expression of versican by hRAN adipocytes thus 
correlates with a differentiated state of mature adipocytes. 
In summary, the identification of these specific proteins 
differentially expressed between hRAT and hRAN, would 
indicate that renal adipose tissue secretes factors that 
protect the organ against an aberrant cellular behavior, and 
that when a tumor appears, this protection is lost. In 
addition, we evaluated the importance of adipose tissue 
microenvironment in the regulation of the biological 
behavior of renal epithelial cells. To this end, we evaluated 
the effects of hRAT-CMs or hRAN-CMs on cell 
proliferation, adhesion, and migration of 786-O, ACHN, 
Caki-1 (tumor) and HK-2 (non-tumor) cell lines. All cell 
lines showed a significant decrease in cell adhesion 
(Figure 5), and increase in cell migration (Figure 6), after 
incubation with hRAT-CMs vs. hRAN- or control-CMs. 
These results suggest that adipokines secreted by hRAT 
(present in the CMs), are able to decrease cell adhesion, 
and stimulate cell migration of both tumor and non-tumor 
renal epithelial cells. This does not exclude though, that 
adipokines and other factors secreted by other tissues (near 
or farther away from the renal tumor), might also be 
promoting RCC development. Interestingly, HK-2, 786-O 
and ACHN cells showed a significant decrease in cell 
migration after incubation with hRAN-CMs vs. control-
CMs (Figure 6). This result would indicate that adipose 
tissue surrounding a normal kidney (hRAN) has the ability 
to reverse, at least partially, the tumorigenic behavior of 
renal tumor epithelial cells. Therefore, it would be 
extremely important to identify those factors responsible 
for this observed effect, and to use them to limit renal 
tumor development. No differences on proliferation of cell 
lines were found after 24 or 48 h of treatment with CMs, 
in accordance with our previous results [11]. In order to 
elucidate the mechanisms underlying the biological effects 
observed in cell lines incubated with the different CMs, 
we assessed if there were changes in the expression of 
different proteins. We found a decrease in the expression 
of AdipoR1 in renal tumor cell lines ACHN and Caki-1 
(from metastatic site) incubated with hRAT-CMs (Figure 
7A). Additionally, an increase in the expression of ObR in 
786-O, ACHN and Caki-1 (tumor cells) incubated with 
hRAT-CMs (Figure 7B) was found. Adiponectin usually 
Figure 8: Effect of CMs from hRAN and hRAT on: pERK (A) and pPI3K (B) expression was evaluated in HK-2, 786-O, ACHN and 
Caki-1 cell lines. HK-2, 786-O, ACHN and Caki-1 cells were grown on 6 well plates, incubated for 24 hs with the different CMs and then 
lysed. Expression of the different proteins was measured by Western blot. ERK (A) and PI3K (B) were used as internal controls. Images 
were analyzed by densitometry Horizontal bars represent the geometric mean of each data set. Vertical bars indicate SEM. *p < 0.001 cells 
incubated with hRAT-CMs vs. hRAN-CMs and control-CMs.
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has an anti-tumor behavior, and leptin increases cellular 
tumorigenicity. Therefore, ours results demonstrate that 
hRAT-CMs modify the phenotype of renal tumor cells 
towards a more tumorigenic behavior. Also, we found that 
hRAT-CMs increase CD44 expression in some tumor cell 
lines (Figure 7C). Numerous studies have shown that 
CD44, a membrane glycoprotein, is involved in processes 
of tumor cell migration and invasion [48, 49]. Moreover, 
CD44 is a marker, together with CD24, of tumor-initiating 
cells or tumor stem cells [50]. Considering this, our results 
could be indicating that hRAT-CMs increase the 
subpopulation of cells with high levels of CD44, and that, 
in this way, promote cellular invasion, resistance to 
treatments and malignancy. Regarding vimentin, this 
protein forms the intermediate filaments of the 
cytoskeleton and, in addition, is a marker of mesenchymal 
cells [51]. In particular, vimentin has received attention in 
recent years because it has been found overexpressed in 
different types of tumor cells, and this overexpression is 
associated with an increase in cell invasion and tumor 
growth [52]. Furthermore, vimentin is a marker of 
epithelial-mesenchymal transition, a process by which 
tumor epithelial cells acquire the ability to migrate, and is 
involved in cell invasion and metastasis [53]. We found 
that hRAT-CMs increase the expression of vimentin in a 
non-tumor cell line (Figure 7D), which indicates that 
factors present in the CMs from hRAT have the ability to 
revert the phenotype of non-tumor epithelial cells to a 
mesenchymal phenotype.
Finally, we evaluated changes in intracellular 
signaling pathways (ERK and PI3K) of normal and tumor 
cell lines incubated with the different conditioned media. 
Ours results showed an increase of pERK in HK-2 and 
786-O cells incubated for 2 h with hRAT-CMs compared 
to hRAN- and control CMs (Figure 8A). In addition, we 
found a significant increase of pPI3K in HK-2, 786-O and 
ACHN cells incubated for 24 h with hRAT-CMs compared 
to hRAN- and control CMs (Figure 8B). These increases 
in pERK and pPI3K levels could at least partially explain 
the observed changes in migration and cell adhesion.
Based on the results presented, we postulate that 
renal peritumoral adipose tissue undergoes a process 
of adaptation to changes locally generated by the 
tumor. Thus, adipose tissue close to the tumor would 
favor tumor progression through factors secreted to its 
microenvironment (hRAT), unlike normal renal adipose 
tissue (hRAN). Specifically, we hypothesize that this 
hRAT, already modified with regard to hRAN, is capable 
of stimulating a protumorigenic behavior of renal 
epithelial cells. Likewise, the hRAN would be able to 
reverse the tumorigenic behavior of renal tumor epithelial 
cells. We acknowledge that the present study has some 
methodological limitations. Firstly, we measured only a 
few of all possible adipokines. We expect to be able to 
identify other relevant factors by means of proteomic 
analysis. Secondly, we have focused only in one of 
the several stromal cell types (adipocytes) that could 
be influencing tumor behavior. Nevertheless, despite 
possible limitations, we believe that the obtained results 
provide relevant information concerning the role of 




Reagents were from Sigma Chemical Co (St. Louis, 
MO, USA), tissue culture flasks, dishes, and multi-well 
plates were from Falcon Orange Scientific (Graignette 
Business Park, Belgium), and culture media from both 
tissue and cell lines and supplements were from Gibco 
BRL (Carlsbad, CA, USA).
Sample collection and handling
Human adipose tissue explants from cancerous 
(hRAT; n = 14) kidneys were obtained from patients 
to whom a partial or total (tumor) nephrectomy was 
performed. Human adipose tissue explants from normal 
kidneys (hRAN; n = 13), were obtained from live kidney 
donors who had not received previous chemotherapy or 
radiotherapy treatment. The median of body mass index 
(BMI) of patients was: 24.2 kg/m2 for patients with renal 
tumor (hRAT), and 26.9 kg/m2 for living kidney donors 
(hRAN). (BMI) (kg/m2) was calculated as weight (kg) 
divided by height (m) squared.
Samples were transported in PBS with gentamicin 
(50 µg/ml) and processed immediately. On average, 2 h 
elapsed from the acquisition of the surgical sample until 
it was processed under a sterile laminar flow hood. The 
project was approved by the Medical School’s ethics 
committee (Universidad Nacional de Cuyo, Argentina). 
All patients gave their informed consent to undergo tissue 
harvesting for this research.
Gene expression by RT-qPCR analysis
Total RNA was extracted from 100 mg of tissue 
using Trizol reagent (Invitrogen, Carlsbad, CA, USA) 
and quantified according to its absorbance at 260nm 
(NanoDrop 2000, Thermo Scientific, Wilmington, USA). 
Contaminating genomic DNA was degraded with DNAse 
RQ1 (Promega, Madison, USA), cDNA was synthesized 
from one microgram of total RNA using 300 pmol oligo-
dT primers, 10 mM dNTP (Thermo Scientific, Wilmington, 
USA) and 200 U M-MLV reverse transcriptase (Promega, 
Madison, USA). Real-time PCR was performed in a final 
volume of 20 uL containing 50 ng cDNA, 3mM MgCl2, 
PCR LightCycler-DNA Master SYBRGreen reaction mix 
(Roche, Indianapolis, USA) and 0.5 mM of each specific 
primers (Table 1). Amplification was performed in a using 
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LightCycler thermocycler (Roche, Indianapolis, USA). 
Controls without reverse transcription were included to 
ensure that amplifications were from mRNA and not from 
genomic DNA. Amplicons were characterized according 
to their melting temperature and size. The mRNA level of 
each target gene was calculated using the 2∆∆Ct method 
and normalized against the mRNA of β-actin.
Immunohistochemistry
10 µm serial cuts were performed on the same tissue 
samples embedded in paraffin used for H&E staining. 
Versican, adiponectin, and leptin expression were studied 
by means of immunohistochemistry. Briefly, hRAN 
and hRAT microtome slides were first deparaffinized, 
and then a heat-mediated antigen retrieval, endogenous 
peroxidase blocking and nonspecific tissue blocking were 
performed. Slides were then incubated with the different 
primary antibodies at 4° C, and after that with an anti-
rabbit biotinylated secondary IgG antibody. Finally, slides 
were incubated with peroxidase-conjugated streptavidin. 
Peroxidase reaction was performed with chromogen 
3,3′-diaminobenzidine (DAB) (DAKO LSAB + Kit, 
HRP). Hematoxylin counter stain was performed. Serial 
cuts incubated in the absence of primary antibody were 
used as negative controls. Images were taken with a Nikon 
Eclipse E200 Microscope fitted with a Micrometric SE 
Premium (Nikon Corp., Japan) digital still camera at 100× 
and 400× magnification. DAB staining quantification in 
the three tissue types was performed in 8–10 fields of each 
preparation as mentioned above.
Preparation of conditioned media (CMs) from 
hRAN and hRAT
Adipose tissues were washed three times with cold 
PBS to remove red blood cells and debris, and weighed. 
hRAN or hRAT were plated in culture flask with M199 
culture medium (Invitrogen™; 1 g tissue/10 ml M199), 
supplemented with gentamicin (50 µg/ml) and incubated 
for 1 h at 37° C in 5% CO2. After that, the medium was 
removed and replaced with fresh medium and the tissues 
were incubated for 24 h. Subsequently, the supernatants 
were collected and cells were removed by centrifugation 
(3 min at 400 × g). Then, supernatants were aliquoted 
into 1-ml fractions and immediately stored at -80° C. 
The control-CMs were obtained from the collection of 
serum-free M199 medium after 24 h of incubation in a 
culture flask at 37° C in 5% CO2.
Treatment with hRAN- and hRAT-CMs
In order to study cell proliferation, migration and 
proteins expression of tumor (786-O, ACHN and Caki-1) 
and non-tumor (HK-2) human renal epithelial cell 
lines, MCs collected were diluted 1:1 in DMEM-F12 
(Invitrogen, UK) 2% fetal bovine serum (FBS; 1% FBS 
final concentration) and the cells were incubated with the 
diluted CMs. The experiments were performed with equal 
volumes of hRAN- and hRAT-CMs. The concentration 
of total protein in those volumes was quantified using 
Bradford reagent.
Culture of tumor and non-tumor renal epithelial 
cell lines
Tumor (786-O, ACHN and Caki-1) and non-tumor 
(HK-2) human renal epithelial immortalized cell lines 
were used. 786-O (ATCC® CRL1932™), ACHN (ATCC® 
CRL1611™), Caki-1
(ATCC® HTB46™) and HK-2 (ATCC® CRL2190™) 
were obtained from the American Type Culture Collection 
(ATCC, Rockville, MD). 786-O is a line derived from a 
primary clear cell adenocarcinoma (primary tumor); and 
both ACHN and Caki-1 are lines derived from metastatic 
sites (pleural effusion and skin respectively. The four cell 
lines were cultured in DMEM-F12 medium with 10% FBS 
and 2 µg/ml insulin; and were maintained at 37° C in 5% 
CO2. The number of generations for HK-2 was 13-16; 
8–12 for 786-O, 10-14 for ACHN, and 18-21 for Caki-1.
Proliferation assay
Tumor (3 × 103 786-O, ACHN or Caki-1 cells/well) 
and non-tumor (5 × 103 HK-2 cells/well) human renal 
epithelial cell lines were incubated on 96-well plates 
Table 1: primer pair sequence are shown for the Forward (F) and Reverse (R) primers used to measure mRNA 
abundance by RT-qPCR
Gen Forward (5′-3′) Reverse (5′-3′) Ct Size (pb)
TM 
(°C) Gene bank
adiponectin TGACTCCACCTTCAGAGGCTTT ATTGACTTTGGGGCTGTTTGGC 35 95 84 NM_004797.2
Leptin TCACCAGGATCAATGACATTTCAC CCCAGGAATGAAGTCCAAACC 35 80 82 NM_000230.2
GADPH GGAGCGAGATCCCTCCAAAAT GGCTGTTGTCATACTTCTCATGG 35 197 89 NM_002046.3
Actin CTGTGGCATCCACGAAACTA AGAAAGGGTGTAACGCAACTA 35 350 89 NM_001101.3
Versican TGAAGACACACAAGACACGG CAACGTCCAAACAAGCCTTC 40 119 86 NM_001126336.2
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with complete DMEM-F12 for 24 h. Then, the four cell 
lines were treated with hRAN-, hRAT- or control-CMs. 
After 24 or 48 h, MTT was added to each well at a final 
concentration of 1 mg/ml and incubated at 37° C for 
2 h. The media/MTT solution was then removed 
without disturbing the attached cells, and accumulated 
formazan in cells dissolved in acidified (4% 1N HCl) 
isopropanol. The absorbance of each sample was 
determined at 570 nm. Each sample was repeated three 
times. Results are expressed as percentage of color 
intensity and normalized to cells grown in control-CMs. 
In addition, we evaluated cell proliferation by the cell 
count technique using Tripan blue in order to identify 
dead cells.
Cell adhesion assay
Adhesion assays were performed following a 
protocol previously reported [54]. Briefly, 96-well plates 
were coated with 100 µl hRAN-, hRAT- or control-CMs 
at 37° C overnight in 5% CO2. These CMs were set in 
three wells and each experiment was repeated three times. 
Plates were then blocked with 1 mg/ml bovine serum 
albumin at 37° C for 1 h. After washing with PBS, 786-O, 
ACHN, Caki-1 and HK-2 cells (5 × 104 cells/well) were 
suspended in serum-free DMEM-F12 medium, seeded 
and allowed to adhere to the CMs factors-coated wells 
at 37° C for 1 h in 5% CO2. Non-adherent cells were 
aspirated and wells washed twice with PBS. Residual 
cells were evaluated by MTT assay. Cell adhesion to 
hRAN-, hRAT-CMs factors was expressed as percentage 
of control-CMs.
Cell migration assay
The effect of hRAN-, hRAT- or control-CMs 
on the motility of tumor and non-tumor human renal 
epithelial cell lines was evaluated by wound-healing and 
by Transwells migration assays. Wound-healing assays: 
786-O, ACHN, Caki-1 and HK-2 cells were grown on 
96-well plates with complete DMEM-F12. Confluent 
cell monolayers were wounded with a pipette tip, washed 
twice with PBS and hRAN-, hRAT- or control-CMs were 
added. Images at time zero (0 hours) were captured to 
record the initial width of the wounds. The recovery of 
the wounded monolayers due to cell migration toward 
the denuded area was evaluated after 6, 12 and 24 h. 
The images were acquired by an inverted phase-contrast 
microscope (Olympus CKX-41) using a 4× objective. 
Quantification was performed using ImageJ (NIH, 
Bethesda, MD, USA) by a polygon selection mode. 
The percentage of the wounded area was determined at 
6 or 12 hs respect to control (0 h). Transwell migration 
assays: 786-O, ACHN, Caki-1 and HK-2 cells (2–9 105 
cells/0.2 ml) were placed into the top transwell with 8 
µm pore membranes (NUNC cat.#140629). They were 
then incubated with hRAN-, hRAT- or control-CMs and 
allowed to transmigrate across the porous membrane for 
20 h. At the end of the assay, inserts were removed and the 
cells were fixed in 4% paraformaldehyde and then stained 
with a 0.1% crystal-violet solution. Tumor and non-tumor 
cells on the upper membrane surface were removed with a 
paper towel. The air-dried membranes were viewed under 
20× magnification and migrated cells were counted in 5 
randomly chosen fields per membrane.
Preparation of cell lysates from renal epithelial 
cells after incubation with hRAN-, hRAT- or 
control-CMs
786-O, ACHN, Caki-1 and HK-2 cells were seeded 
in six-well plates in DMEM-F12 complete medium. 
When cells reached 75–80% confluence, the medium was 
aspirated and cells were washed twice with PBS. Then, 
cells were incubated at 37° C for 24 h either with hRAN-, 
hRAT- or control-CMs (50% CM, 50% DMEM-F12 2% 
FSB). Cells were lysed with Ripa buffer, pelleted by 
centrifugation at 4° C and stored at −80° C.
Western blot analysis
Protein expression in epithelial cell lines
In order to evaluate protein expression levels, 
Western blots were performed. AdipoR1, ObR, CD44, 
vimentin, ERK, pERK, PI3K and pPI3K were measured 
after incubation of the epithelial cell lines with the 
different CMs obtained. In order to lyse cells, Ripa buffer 
was used (Tris 10 mM pH 7,5; NaCl 150 mM; sodium 
vanadate 2 mM; sodium deoxycholate; SDS 0,1%; igepal 
1%; protease inhibitors). Total protein in samples was 
quantified by Bradford method. Proteins were separated 
in a SDS-PAGE 12 or 18% gel, and electrotransferred to a 
nitrocellulose membrane (Amersham). The membrane was 
later blocked with bovine serum albumin (Sigma-Aldrich, 
0055K) and then incubated with the different antibodies 
ON at 4° C. The membranes were later washed, and 
incubated with proper secondary antibodies conjugated to 
HRP. Antibody complexes were visualized by means of 
chemiluminescence (ECL; GE Helathcare). Bands were 
quantified by densitometry using FIJI Image processing 
package [24]. In the cell extracts, β-actin level in samples 
was used to determine that equal quantities of proteins 
were loaded in the gel.
Protein expression in CMs
In addition, adiponectin, ADAMTS1 and perilipin 1 
expression was measured in hRAN- and hRAT-CMs. Total 
protein in samples was quantified by Bradford method. 
Proteins were separated in a SDS-PAGE 12% gel, and 
electrotransferred, afterwards we performed the same 
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protocol described for cells. The western blot assay for the 
hRAN- and hRAT-CMs was performed by loading equal 
volumes of each CM (40 µl).
Statistical methods
The statistical significance between different 
experimental conditions was evaluated by t-test or one-way 
ANOVA. Tukey´s post-hoc tests were performed within 
each individual treatment. The results are presented as mean 
± SEM. Results were considered significant at p < 0.05.
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